oncoFISH cervical Test Overview

Ikonisys Clinical Laboratories offers the oncoFISH cervical test, a laboratory developed test, which can be used in conjunction with other testing to better manage patients previously diagnosed with an LSIL result. oncoFISH cervical is available exclusively from Ikonisys Clinical Laboratories.

The oncoFISH cervical test is an automated qualitative fluorescence in situ hybridization (FISH) test for determining the acquisition of specific chromosomal aneuploidies within the 3q26 region in cytological specimens revealing LSIL.

oncoFISH cervical provides information to assist the physician in the clinical management of LSIL prior to colposcopy.

Approximately 10% of patients diagnosed with LSIL will progress to HSIL, 60% will regress to normal and 30% will remain LSIL (Nasiell K, et al. 1986, Ostor AG, et al. 1993, Melnikow J, et al. 1998, Holowaty P, et al. 1999, Wright TC, et al. 2007.)

Historically, it has not been possible to identify which patients will progress or not. The oncoFISH cervical test provides a predictive tool to aid the clinician in managing an LSIL diagnosis.

It is recommended that the physician use the oncoFISH cervical test results as part of the patient's overall clinical assessment and in the context of current clinical practice guidelines. oncoFISH cervical is not intended to be used as a stand-alone test.

What Our Customers Are Saying

"Until now, physicians had no tool to help assess cervical disease risk for women diagnosed with low grade squamous lesions. oncoFISH cervical is an advancement in risk stratification, which will facilitate improved patient management for a woman diagnosed with an abnormal Pap. We were pleased to be the first to offer oncoFISH cervical to our physicians."

Dr. Bruce Dziura, Chief of Cytopathology of New England Pathology Associates at Mercy Medical Center, Springfield, Mass.


Note: oncoFISH cervical is available exclusively as a Laboratory Developed Test (LDT) through the Ikonisys Clinical Laboratory. This test was developed and its performance characteristics determined by Ikonisys, Inc.

Download the oncoFISH cervical brochure